Reports on the anticipated move of the U.S. Food and Drug Administration (FDA) to license Cambridge, Massachusetts-based Biogen's psoriasis drug Amevive (alefacept). Recommendation of the FDA's dermatological and ophthalmic advisory panel; Likely approval of three other biologicals.